Successful exit – Proteintech acquires ChromoTek
The acquisition enables Proteintech to expand its next-generation antibody tools
21-Oct-2020 -
High-Tech Gründerfonds and Bayern Kapital have sold their shares in ChromoTek after having spent 10 years at the start-up’s side. ChromoTek is the market leader in nanobodies — high-performance recombinant reagents that are used for breakthrough research discoveries. The combined companies will ...
antibodies
nanobodies
reagents
+1